Previous 10 | Next 10 |
2023-06-12 16:13:12 ET Summary Novartis announced the acquisition of Chinook Therapeutics for $3.5 billion, boosting its pipeline and expanding into the kidney disease market. The deal can be paid for with around three months' worth of Novartis' free cash generation, and the compa...
2023-06-12 13:27:35 ET Shares of clinical-stage biotechs Olema Pharmaceuticals ( NASDAQ: OLMA ) and Arvinas ( NASDAQ: ARVN ) rose on Monday as Wall Street reacted to comments from Jefferies and Oppenheimer on a class of breast cancer drugs called oral selective estrogen rece...
2023-06-12 12:30:19 ET The major market averages were higher during Monday's midday session on expectations that the Fed will hold off on raising interest rates at its policy meeting on Wednesday. Tracking individual stocks, Oracle ( NYSE: ORCL ), SentinelOne ( NYSE: S )...
2023-06-12 11:00:58 ET Avrobio ( NASDAQ: AVRO ) said it has completed the sale of its gene therapy program for the treatment of cystinosis to Novartis ( NYSE: NVS ) for $87.5M in cash, which should extend the biotech company's cash runway into Q4 2024. The sale was for A...
2023-06-12 10:43:42 ET Kidney disease drug developer Chinook Therapeutics ( KDNY ) added ~56% on Monday after announcing a $3.5B buyout deal with Novartis ( NVS ), sending the shares of its rival Vera Therapeutics ( NASDAQ: VERA ) sharply higher. Per the terms, the S...
2023-06-12 02:56:04 ET Novartis ( NVS ) will acquire biopharmaceutical company, Chinook Therapeutics ( KDNY ) for $40 per share in cash, or a total of $3.2B. This offer represents a premium of 83% to Chinook’s 60-day volume-weighted average stock price and 67% to...
2023-06-08 23:21:36 ET Summary The article analyzes Amgen's financial performance, including balance sheet trends, valuation models, and competition & margin trends. We'll discuss AMGN's dividend and free cash flow of this large, very well-covered dividend growth stock. Am...
2023-06-08 17:27:08 ET Summary Today, we take our first in-depth look at a developmental concerned called Ideaya Biosciences, Inc. Ideaya Biosciences is moving forward a diverse pipeline of drug candidates based on its focus on synthetic lethality. An investment analysis follo...
2023-06-08 07:41:22 ET Ahead of its Capital Markets Day in New York on Thursday, Sandoz, the generics drug business of Novartis ( NYSE: NVS ), announced plans to raise its sales growth and EBITDA margins following its planned spinoff expected in H2 2023. The company focused on o...
2023-06-08 07:39:39 ET Summary We analyzed Novartis pipeline growth versus patent expiration. Positive adjuvant data for Kisqali could accelerate market share shifts. Novartis' equal weight rating is due to high margin sales lost to generics and risks from US healthcare reform...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...